
Sally C. Medley
Examiner (ID: 2197)
| Most Active Art Unit | 2104 |
| Art Unit(s) | 2104, 2836 |
| Total Applications | 293 |
| Issued Applications | 218 |
| Pending Applications | 16 |
| Abandoned Applications | 59 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
| 08/482436 | METHOD FOR SCREENING FOR RECEPTOR AGONISTS AND ANTAGONISTS | Jun 6, 1995 | Abandoned |
Array
(
[id] => 3770277
[patent_doc_number] => 05817307
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1998-10-06
[patent_title] => 'Treatment of bacterial infection with oral interferon-.alpha.'
[patent_app_type] => 1
[patent_app_number] => 8/484376
[patent_app_country] => US
[patent_app_date] => 1995-06-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6963
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 97
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/817/05817307.pdf
[firstpage_image] =>[orig_patent_app_number] => 484376
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/484376 | Treatment of bacterial infection with oral interferon-.alpha. | Jun 6, 1995 | Issued |
Array
(
[id] => 4018897
[patent_doc_number] => 05882640
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1999-03-16
[patent_title] => 'Treatment of hyperallergenic response with oral interferon'
[patent_app_type] => 1
[patent_app_number] => 8/475753
[patent_app_country] => US
[patent_app_date] => 1995-06-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7005
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 126
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/882/05882640.pdf
[firstpage_image] =>[orig_patent_app_number] => 475753
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/475753 | Treatment of hyperallergenic response with oral interferon | Jun 6, 1995 | Issued |
Array
(
[id] => 3868999
[patent_doc_number] => 05824300
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1998-10-20
[patent_title] => 'Treatment of neoplastic disease with oral interferon'
[patent_app_type] => 1
[patent_app_number] => 8/479958
[patent_app_country] => US
[patent_app_date] => 1995-06-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7008
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 115
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/824/05824300.pdf
[firstpage_image] =>[orig_patent_app_number] => 479958
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/479958 | Treatment of neoplastic disease with oral interferon | Jun 6, 1995 | Issued |
Array
(
[id] => 3993180
[patent_doc_number] => 05858347
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1999-01-12
[patent_title] => 'Therapeutic methods using fusion proteins between interleukin-3 (IL-3) variants and other hematopoietic factors'
[patent_app_type] => 1
[patent_app_number] => 8/470775
[patent_app_country] => US
[patent_app_date] => 1995-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 41017
[patent_no_of_claims] => 53
[patent_no_of_ind_claims] => 22
[patent_words_short_claim] => 89
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/858/05858347.pdf
[firstpage_image] =>[orig_patent_app_number] => 470775
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/470775 | Therapeutic methods using fusion proteins between interleukin-3 (IL-3) variants and other hematopoietic factors | Jun 5, 1995 | Issued |
Array
(
[id] => 4081206
[patent_doc_number] => 06017523
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 2000-01-25
[patent_title] => 'Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides'
[patent_app_type] => 1
[patent_app_number] => 8/471039
[patent_app_country] => US
[patent_app_date] => 1995-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 16
[patent_no_of_words] => 110117
[patent_no_of_claims] => 90
[patent_no_of_ind_claims] => 24
[patent_words_short_claim] => 900
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/017/06017523.pdf
[firstpage_image] =>[orig_patent_app_number] => 471039
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/471039 | Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides | Jun 5, 1995 | Issued |
Array
(
[id] => 4134495
[patent_doc_number] => 06060047
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 2000-05-09
[patent_title] => 'Co-administration of interleukin-3 mutant polypeptides with CSF\'s for multi-lineage hematopoietic cell production'
[patent_app_type] => 1
[patent_app_number] => 8/471045
[patent_app_country] => US
[patent_app_date] => 1995-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 5
[patent_no_of_words] => 56534
[patent_no_of_claims] => 31
[patent_no_of_ind_claims] => 13
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/060/06060047.pdf
[firstpage_image] =>[orig_patent_app_number] => 471045
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/471045 | Co-administration of interleukin-3 mutant polypeptides with CSF's for multi-lineage hematopoietic cell production | Jun 5, 1995 | Issued |
Array
(
[id] => 3697099
[patent_doc_number] => 05674494
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1997-10-07
[patent_title] => 'Treating non-malignant disease states with IL-2 receptor-specific substances'
[patent_app_type] => 1
[patent_app_number] => 8/485554
[patent_app_country] => US
[patent_app_date] => 1995-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 3930
[patent_no_of_claims] => 32
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/674/05674494.pdf
[firstpage_image] =>[orig_patent_app_number] => 485554
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/485554 | Treating non-malignant disease states with IL-2 receptor-specific substances | Jun 5, 1995 | Issued |
Array
(
[id] => 4002542
[patent_doc_number] => 05858969
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1999-01-12
[patent_title] => 'Therapeutic methods employing sialylated glycoforms of soluble complement receptor 1 (SCR 1)'
[patent_app_type] => 1
[patent_app_number] => 8/470867
[patent_app_country] => US
[patent_app_date] => 1995-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 12
[patent_no_of_words] => 14192
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 12
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/858/05858969.pdf
[firstpage_image] =>[orig_patent_app_number] => 470867
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/470867 | Therapeutic methods employing sialylated glycoforms of soluble complement receptor 1 (SCR 1) | Jun 5, 1995 | Issued |
Array
(
[id] => 4140636
[patent_doc_number] => 06030812
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 2000-02-29
[patent_title] => 'Fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors'
[patent_app_type] => 1
[patent_app_number] => 8/468609
[patent_app_country] => US
[patent_app_date] => 1995-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 7
[patent_no_of_words] => 106732
[patent_no_of_claims] => 66
[patent_no_of_ind_claims] => 13
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/030/06030812.pdf
[firstpage_image] =>[orig_patent_app_number] => 468609
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/468609 | Fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors | Jun 5, 1995 | Issued |
Array
(
[id] => 3937945
[patent_doc_number] => 05997857
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1999-12-07
[patent_title] => 'Co-administration of interleukin-3 mutants with colony stimulating factors'
[patent_app_type] => 1
[patent_app_number] => 8/470509
[patent_app_country] => US
[patent_app_date] => 1995-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 40343
[patent_no_of_claims] => 50
[patent_no_of_ind_claims] => 18
[patent_words_short_claim] => 527
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/997/05997857.pdf
[firstpage_image] =>[orig_patent_app_number] => 470509
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/470509 | Co-administration of interleukin-3 mutants with colony stimulating factors | Jun 5, 1995 | Issued |
Array
(
[id] => 4085279
[patent_doc_number] => 06132991
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 2000-10-17
[patent_title] => 'Human interleukin-3 (IL-3) variant fusion proteins'
[patent_app_type] => 1
[patent_app_number] => 8/469124
[patent_app_country] => US
[patent_app_date] => 1995-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 42988
[patent_no_of_claims] => 60
[patent_no_of_ind_claims] => 10
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/132/06132991.pdf
[firstpage_image] =>[orig_patent_app_number] => 469124
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/469124 | Human interleukin-3 (IL-3) variant fusion proteins | Jun 5, 1995 | Issued |
Array
(
[id] => 3831456
[patent_doc_number] => 05814485
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1998-09-29
[patent_title] => 'Production of interferon-.beta. (IFN-.beta.) in E. coli'
[patent_app_type] => 1
[patent_app_number] => 8/477310
[patent_app_country] => US
[patent_app_date] => 1995-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 7
[patent_no_of_words] => 14154
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 97
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/814/05814485.pdf
[firstpage_image] =>[orig_patent_app_number] => 477310
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/477310 | Production of interferon-.beta. (IFN-.beta.) in E. coli | Jun 5, 1995 | Issued |
Array
(
[id] => 4102870
[patent_doc_number] => 06022535
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 2000-02-08
[patent_title] => 'Treatment of hematopoietic disorders with fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors'
[patent_app_type] => 1
[patent_app_number] => 8/469318
[patent_app_country] => US
[patent_app_date] => 1995-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 7
[patent_no_of_words] => 106639
[patent_no_of_claims] => 62
[patent_no_of_ind_claims] => 31
[patent_words_short_claim] => 92
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/022/06022535.pdf
[firstpage_image] =>[orig_patent_app_number] => 469318
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/469318 | Treatment of hematopoietic disorders with fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors | Jun 5, 1995 | Issued |
Array
(
[id] => 4406122
[patent_doc_number] => 06238889
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 2001-05-29
[patent_title] => 'Molecular cloning and expression of the Pro8 isoform of human IL-3'
[patent_app_type] => 1
[patent_app_number] => 8/470369
[patent_app_country] => US
[patent_app_date] => 1995-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 32
[patent_figures_cnt] => 35
[patent_no_of_words] => 18185
[patent_no_of_claims] => 34
[patent_no_of_ind_claims] => 8
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/238/06238889.pdf
[firstpage_image] =>[orig_patent_app_number] => 470369
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/470369 | Molecular cloning and expression of the Pro8 isoform of human IL-3 | Jun 5, 1995 | Issued |
Array
(
[id] => 3772974
[patent_doc_number] => 05817486
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1998-10-06
[patent_title] => 'Recombinant human interleukin-3 (IL-3) multiple mutation polypeptides'
[patent_app_type] => 1
[patent_app_number] => 8/469319
[patent_app_country] => US
[patent_app_date] => 1995-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 25
[patent_no_of_words] => 97509
[patent_no_of_claims] => 130
[patent_no_of_ind_claims] => 22
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/817/05817486.pdf
[firstpage_image] =>[orig_patent_app_number] => 469319
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/469319 | Recombinant human interleukin-3 (IL-3) multiple mutation polypeptides | Jun 5, 1995 | Issued |
Array
(
[id] => 3551483
[patent_doc_number] => 05543141
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1996-08-06
[patent_title] => 'Therapeutic methods using interleukin-3 (IL-3) human/murine hybrid polypeptides'
[patent_app_type] => 1
[patent_app_number] => 8/466647
[patent_app_country] => US
[patent_app_date] => 1995-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 20
[patent_no_of_words] => 27583
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 105
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/543/05543141.pdf
[firstpage_image] =>[orig_patent_app_number] => 466647
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/466647 | Therapeutic methods using interleukin-3 (IL-3) human/murine hybrid polypeptides | Jun 5, 1995 | Issued |
Array
(
[id] => 4182306
[patent_doc_number] => 06093395
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 2000-07-25
[patent_title] => 'Co-administration of interleukin-3 mutant polypeptides with CSF\'s for multi-lineage hematopoietic cell production'
[patent_app_type] => 1
[patent_app_number] => 8/469712
[patent_app_country] => US
[patent_app_date] => 1995-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 5
[patent_no_of_words] => 56517
[patent_no_of_claims] => 56
[patent_no_of_ind_claims] => 24
[patent_words_short_claim] => 249
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/093/06093395.pdf
[firstpage_image] =>[orig_patent_app_number] => 469712
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/469712 | Co-administration of interleukin-3 mutant polypeptides with CSF's for multi-lineage hematopoietic cell production | Jun 5, 1995 | Issued |
Array
(
[id] => 4098365
[patent_doc_number] => 06051217
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 2000-04-18
[patent_title] => 'Therapeutic uses of interleukin-3 (IL-3) multiple mutation polypeptides'
[patent_app_type] => 1
[patent_app_number] => 8/470081
[patent_app_country] => US
[patent_app_date] => 1995-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 25
[patent_no_of_words] => 115966
[patent_no_of_claims] => 132
[patent_no_of_ind_claims] => 36
[patent_words_short_claim] => 925
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/051/06051217.pdf
[firstpage_image] =>[orig_patent_app_number] => 470081
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/470081 | Therapeutic uses of interleukin-3 (IL-3) multiple mutation polypeptides | Jun 5, 1995 | Issued |
Array
(
[id] => 3525467
[patent_doc_number] => 05541103
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 1996-07-30
[patent_title] => 'CD34+ peripheral blood progenitor cells obtained by ex vivo expansion'
[patent_app_type] => 1
[patent_app_number] => 8/467555
[patent_app_country] => US
[patent_app_date] => 1995-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 5
[patent_no_of_words] => 3668
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/05/541/05541103.pdf
[firstpage_image] =>[orig_patent_app_number] => 467555
[rel_patent_id] =>[rel_patent_doc_number] =>) 08/467555 | CD34+ peripheral blood progenitor cells obtained by ex vivo expansion | Jun 5, 1995 | Issued |